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Abstract
Background: Chemokine (C–C motif) ligand 17 (CCL17) is a chemokine mainly produced by myeloid dendritic cells.
It is a ligand for CC chemokine receptor 4 (CCR4) and CC chemokine receptor 8 (CCR8). The aim of this study was
to investigate prognostic values of CCL17 expression in patients with clear cell renal cell carcinoma (ccRCC).
Methods: The study included 286 patients with ccRCC. CCL17 expression was analyzed by immunohistochemistry
on tissue microarrays. Prognostic values of CCL17 expression and patients’ clinical outcomes were evaluated.
Results: Kaplan-Meier method showed that low CCL17 expression was associated with worse patient overall survival
(OS) and recurrence-free survival (RFS) (OS, P = 0.002; RFS, P = 0.007). Low CCL17 expression was an adverse independent
risk factor for OS and RFS in multivariate analyses (OS, P = 0.006, P = 0.011 for bootstrap; RFS, P = 0.002, P = 0.025
for bootstrap). We constructed two nomograms incorporating parameters derived from multivariate analyses to
predict patients’ OS and RFS (OS, c-index 0.799; RFS, c-index 0.787) and they performed better than existed integrated
models.
Conclusion: Low CCL17 expression is a potential independent adverse prognostic biomarker for recurrence and
survival of patients with ccRCC after nephrectomy. Established nomograms based on this information could help
predict ccRCC patients’ OS and RFS.
Keywords: Chemokine (C–C motif) ligand 17, Clear cell renal cell carcinoma, Prognostic factor, Overall survival,
Recurrence-free survival
Background
Renal cell carcinoma (RCC) is the most common malig-
nant cancer in the adult kidney and accounts for 2 to 3%
of all malignancies in adults [1]. Clear-cell RCC (ccRCC)
is the major histological subtype according to the WHO
classification, which accounts for 80–90% of all RCC pa-
tients [2]. Around one third of the patients who under-
went curative surgeries would develop recurrences or
metastases afterwards [3]. Several prognostic factors and
integrated staging systems have been developed for RCC
patients such as TNM stage, Fuhrman grade and several
integrated models like University of California Integrated
Staging System (UISS) and Mayo Clinic stage, size, grade
and necrosis (SSIGN) score [4]. Unfortunately, these
models are not accurate enough due to the genetic com-
plexity and heterogeneity of the disease [5]. Improved
predictive models of survival for ccRCC are needed.
Numerous evidences indicate that chemokines play
pleiotropic roles in tumor cell biology [6]. Chemokine
(C–C motif ) ligand 17 (CCL17), also known as thymus
and activation-regulated chemokine (TARC) [7], is a
chemokine produced by myeloid dendritic cells, endo-
thelial cells, bronchial epithelial cells and several tumor
cells [8]. It is a ligand for CC chemokine receptor 4
(CCR4) and CC chemokine receptor 8 (CCR8). It is able
to recruit T cells particularly Th2 cells and activate other
antigen-presenting cells [9]. Researchers recently proved
that CCL17 was involved in recruiting cytotoxic T cells
by binding to CCR4 [10] and activating CD8+ T cells
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through dendritic cells [11]. These findings indicate that
CCL17 is able to enhance antitumor immunity. We won-
dered whether chemokine CCL17 could act as a promising
biomarker candidate for RCC. The role of CCL17 in the
development of ccRCC remains unknown so we analyzed
the impact of CCL17 expression on patients’ overall sur-
vival (OS) and recurrence-free survival (RFS) in a large
cohort of ccRCC patients.
Methods
Patients and specimens
A total of 286 ccRCC patients who received nephrectomy
in Zhongshan Hospital, Fudan University during Jan 2005
and Jun 2007 were enrolled in our study. Clinical Research
Ethics Committee of Zhongshan Hospital, Fudan Univer-
sity had approved the study and granted permissions to
access the patient records. Written and informed consent
was obtained from each individual enrolled in the study.
Clinicopathological variables included age, gender, tumor
size, TNM stage, Fuhrman grade, Eastern Cooperative
Oncology Group performance status (ECOG PS) and ne-
crosis. SSIGN score and UISS score were assessed for each
patient. Patients should meet the primary criteria of
having pathologically proved ccRCC, having received
nephrectomy and having available Formalin Fixed Paraffin
Embedded (FFPE) specimen of tumor mass (≥1 cm3).
Patients who had other former malignant tumors, peri-
operative mortalities, histories of adjuvant or neo-adjuvant
therapies including targeted therapies, mixed type renal
cancer or bilateral renal cancer were excluded. Samples
with over 80% necrotic or hemorrhagic area were ex-
cluded either.
Data collection
Patients’ OS was defined as the time of nephrectomy to
the time of death or last follow up while RFS was calcu-
lated from the time of nephrectomy to the time of recur-
rence. Recurrence was confirmed by imaging, biopsy or
physical examination. There were altogether 24 patients
excluded from RFS analysis because of missing data of
recurrence state or preoperational metastases. Patients
were followed up every 3 months during the first 5 years
after operation and once a year thereafter. Data was cen-
sored until Jan 30, 2015, the last follow up time or the
time when patient died. Two pathologists (Yuan J. and
Jun H.) reviewed the H&E slides to reconfirm histo-
logical subtype, stage, and Fuhrman grade. They con-
firmed ccRCC histological subtypes according to the
2014 EAU guidelines [2]. Tumor stage was classified ac-
cording to the 2010 AJCC TNM classification [12].
Fuhrman grade and necrosis were reported according to
2012 ISUP consensus [13]. The SSIGN, UISS and SSIGN
localized (Leibovich) score were applied to stratify pa-
tients into different risk groups [14–16].
Immunohistochemistry and evaluation
We constructed tissue microarrays (two cores for one
tumor block) with formalin-fixed, paraffin embedded
surgical specimens. Immunohistochemical staining was
performed on tissue microarrays with protocols de-
scribed previously [17]. Antibodies against CCL17
(Anti-TARC antibody, ab182793, Abcam, diluted 1/100)
and visualization reagent (DakoEnVision Detection Sys-
tem) were used. The specificity of the antibody was
confirmed by western blot using RCC cell lines. We
used Olympus CDD camera, Nikon eclipse Ti-s micro-
scope (×200magnification and × 400magnification) and
NIS-Elements F3.2 software to record the staining re-
sults. We took three independent shots and chose the
strongest for each tumor core. The intensity of immu-
nohistochemical staining of CCL17 was scored by two
urologists unaware of the patients’ clinical features and
outcomes using Image-Pro Plus version6.0 software
(Media Cybernetics Inc., Bethesda, MD, USA). The
pooled IOD mean of the six spots in two tumor cores
was regarded as the final staining intensity for each
block. We defined IOD score of 8461 as the cutoff
value for high and low expression with X-tile software
according to the ‘minimum P-value method’ on the
basis of its relation with OS [18].
Statistical analyses
Statistical analyses were performed using SPSS Statis-
tics 21.0 (SPSS Inc., Chicago, IL), R software version
3.0.2 with the “rms”, “smoothHR” and “phenoTest” [19]
package (R Foundation for Statistical Computing,
Vienna, Austria) and Stata (version 12.1; StataCorp LP,
TX, USA). Mann-Whitney U test, Pearson’s chi-square
test, Fisher’s exact test or Cochran-Mantel-Haenszel χ2
test was used to compare clinicopathological parame-
ters of the patients. Kaplan–Meier analysis was applied
to plot the survival curve. Log-rank test was used to
compare patient survival between subgroups. Log-rank
P values were corrected using the formula proposed by
Altman and colleagues [20] since P values obtained
through “minimum p value method” might be overesti-
mated. Numbers at risk were calculated at the begin-
ning of each time period. The Cox proportional
hazards regression model was used to perform univari-
ate and multivariate analyses. Besides, 1000 bootstrap
resamples were performed for reducing overfitting bias.
Two nomograms were constructed to predict the OS
and RFS. We calculated concordance index to compare
the prognostic or predictive accuracy of different
models. Hanley-McNeil test was applied to compare
the difference between c-indexes. All statistical tests
were 2-sided and P < 0.05 was considered statistically
significant.
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Results
Expression of CCL17 and its correlation with
clinicopathological characteristics
We first evaluated CCL17 expression by immunohisto-
chemistry staining analysis in 286 ccRCC patients.
CCL17 expression was predominantly found on the
cytoplasm of tumor cells and the intensity of the staining
was variable (Fig. 1a and b). We illustrated the smooth
estimated HR of CCL17 expression (+1 IOD score) on
patients’ OS (Fig. 1c). According to the cutoff value
(8461) derived from IOD scores and “minimum p value
method”, 143 of 286 patients were assigned to the low
CCL17 expression group and others were assigned to
the high CCL17 expression group. The smooth HR
curve displayed a significant and stable prognostic differ-
ence between the high and low CCL17 expression
patient groups with the cutoff value as a reference
(Fig. 1d). The curve of smooth estimates did not fluctu-
ate much and log hazard ratio kept decreasing with the
increase of IOD scores of CCL17 expression, which indi-
cated that a two-level classification was appropriate
(Fig. 1c). CCL17 expression was significantly associated
with ECOG PS (P = 0.003) while its correlation with
other clinicopathological characteristics did not meet
statistical significance. The associations between CCL17
expression and clinicopathological features were summa-
rized in Table 1. The median follow-up time was
90.87 months (range 2.63-120.47).
High CCL17 expression is associated with better
prognosis
Kaplan-Meier survival analysis was performed to compare
OS and RFS according to CCL17 expression. P values
were corrected [20]. Patients with high CCL17 expres-
sion had a significantly better OS (P = 0.002) and RFS
(P = 0.007) than patients with low CCL17 expression
(Fig. 2a and d). We then performed univariate and
multivariate analyses to further assess whether CCL17
expression was an independent prognostic factor of OS
and RFS. Univariate analysis showed that IOD score as
a continuous viable was significantly associated with
OS and RFS. CCL17 expression as a dichotomous variable
was also a risk factor for both OS and RFS in univariate
analysis (Additional file 1: Table S1). Furthermore, in
multivariate analysis, high CCL17 expression was also a
favorable independent risk factor for both OS and RFS
(OS, HR, 0.504, 95% CI, 0.309–0.824, P = 0.006, P = 0.011
for bootstrap; RFS, HR, 0.448, 95% CI, 0.267–0.751, P =
0.002, P = 0.025 for bootstrap). Pathological T stage,
Fig. 1 CCL17 expression in clear cell renal cell carcinoma (ccRCC) tissues and Smooth estimates of HR (+1 IOD). Representative CCL17
immunohistochemical (IHC) images of ccRCC tumor tissues with low CCL17 expression (a) and high CCL17 expression (b). Smooth estimates of
HR (+1 IOD) showed a higher risk of death or recurrence for patients with lower CCL17 expression (c), (e). Smooth estimates of HR (using IOD = 8461
as a reference) showed a significant and stable prognostic difference between patients with high/low CCL17 expression (d), (f). Dashed lines: 95%
confidence bands
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distant metastasis, necrosis, Fuhrman grade and ECOG PS
were significantly associated with OS and RFS (Table 2).
Extension of Prognostic Model with CCL17 expression for
ccRCC
As is shown in Fig. 2, the SSIGN/SSIGN (localized) score
was applied to classify patients into two risk levels: 0–3
(low), ≥4 (mediate and high) for OS analysis and 0–2
(low), ≥3 (mediate and high) for RFS analysis. High
CCL17 expression displayed as a good prognostic factor
in intermediated- and high-risk groups in both OS and
RFS analyses (OS, P = 0.004; RFS, P = 0.006). Then, we
sought to investigate whether the incorporation of the
CCL17 expression into TNM stage, UISS, and SSIGN
would improve their predictive accuracy by calculating the
C-index (Table 3). CCL17 expression information could
add additional power into several existed RCC prognos-
tic models (OS, P = 0.003, RFS, P = 0.002 for TNM; OS,
P = 0.006, RFS, P = 0.001 for SSIGN; OS, P < 0.001, RFS,
P = 0.001 for UISS) (Table 3).
Prognostic Nomograms of ccRCC
We constructed two nomograms to predict OS and RFS
at 5 and 8 years after nephrectomy (Fig. 3a, d). The pre-
dictors were based on the validated multivariate analyses
(Table 2), including pathological T stage, distant metas-
tasis, Fuhrman grade, necrosis status, ECOG PS and
CCL17 expression. The C-index showed a good predictive
accuracy for nomograms in both OS and RFS (OS, C-
index 0.799; RFS, C-index 0.787). The nomogram to
predict OS showed better prognostic capability com-
pared with SSIGN (Nomogram vs SSIGN, P < 0.001)
and UISS (Nomogram vs UISS, P < 0.001). In terms of
RFS, the second nomogram also performed better than
SSIGN (Nomogram vs SSIGN, P < 0.001) and UISS
(Nomogram vs UISS P = 0.001). Calibration curves for
nomogram predicted 5-year and 8-year OS (Fig. 3b, c)
and RFS (Fig. 3e, f ) were established and the plots dis-
played good consistency between the predicted and
actual observation of patients’ survival.
Discussion
In this study, we found that CCL17 was predominantly
expressed on cytoplasm of tumor cells through immuno-
chemistry, and high CCL17 expression turned out to be
positively correlated with a better prognosis. What’s more,
CCL17 expression was an independent prognostic factor
for OS and RFS of ccRCC patients. The combination of
CCL17 expression and current prognostic models like
TNM stage, UISS and SSIGN was able to enhance prog-
nostic accuracy. In the end, we generated two nomograms
by incorporating CCL17 with other clinicopathological
parameters derived from multivariate analysis to predict
patients’ OS and RFS. Comparisons by C-indexes showed
Table 1 Clinical characteristics of patients according to CCL17
expression
Characteristics Patients CCL17 expression
n % Low High P-value
All patients 286 100 143 143
Age, years 0.811a
mean ± SD 55.37 ± 13.24 55.69 ± 13.46 55.05 ± 13.06
Gender 0.368b
Female 87 30.4 47 40
Male 199 69.6 96 103
Tumor size, cm 0.173a
mean ± SD 4.81 ± 2.67 5.04 ± 2.76 4.58 ± 2.56
Pathological T stage 0.301c
pT1 181 63.3 85 96
pT2 26 9.1 16 10
pT3 75 26.2 40 35
pT4 4 1.4 2 2
Pathological N stage 1.000b
pNx 240 83.9 120 120
pN0 44 15.4 22 22
pN1 2 0.7 1 1
Distant metastasis 0.063b
No 271 94.8 132 139
Yes 15 5.2 11 4
TNM stage 0.122c
I 175 61.2 79 96
II 23 8.0 13 10
III 69 24.1 35 34
IV 19 6.6 14 5
Fuhrman grade 0.456c
1 32 11.2 17 15
2 209 73.1 99 110
3 41 14.3 25 16
4 4 1.4 2 2
Necrosis 0.866b
Absent 245 85.7 123 122
Present 41 14.3 20 21
ECOG PS 0.003b
0 208 72.7 93 115
≥ 1 78 27.3 50 28
UISS category 0.277c
Low risk 119 41.6 54 65
Mediate risk 127 44.4 63 64
High risk 40 14.0 24 16
SSIGN category 0.143c
0–3 218 76.2 105 113
5–7 62 21.8 33 29
8+ 6 2.1 5 1
ECOG PS Eastern Cooperative Oncology Group performance status
P-value < 0.05 was regarded as statistically significant
aMann-Whitney U test for continuous variables, bχ2 test or Fisher’s exact test,
cCochran-Mantel-Haenszel χ2 test
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that the two nomograms performed better than current
prognostic models.
As a member of the CC-motif chemokine family, CCL17
is actively secreted by immune cells. CCL17 binds to the
G-protein coupled CCR4 and CCR8 and serves for the re-
cruitment and migration of these receptor-expressing cells
[21, 22]. CCL17 was considered to attract CCR4+ Treg
cells to the tumor. CCL17 created a favorable environment
where tumor cells could escape from host immune re-
sponses in some type of cancers [23]. Different functions
of CCL17 are being discovered these years. CCL17 pro-
duced by dendritic cells is able to attract naive cytotoxic T
lymphocytes expressing CCR4 and enhance cytotoxicity
[10]. It is also a mediator of CD8+ T cell activation
through dendritic cells [11]. The prognostic significance of
CCL17 varies with the type of malignancy. CCL17 high ex-
pression in tumor cells predicts poor survival in patients
with hepatocellular carcinoma [24]. Elevated serum
level of CCL17 predicts better survival in renal cell
carcinoma after peptide vaccination [25] and melan-
oma carcinoma [26]. Researchers treated 68 subjects
with IMA901, a therapeutic vaccine for RCC consisting
of multiple tumor associated peptides. Among 300
serum biomarkers, researchers identified that low apo-
lipoprotein A-I and CCL17 predicted worse IMA901
treatment response and overall survival [25]. Our study
revealed that low CCL17 expression was also associ-
ated with poor patients’ survival without IMA901
treatment.
CCR4 is expressed by CD4+ T cells, CD8+ cytotoxic T
lymphocytes, natural killer cells, macrophages and sub-
sets of DCs [27]. Mogamulizumab (KW-0761) is a hu-
manized antiCCR4 mAb approved for treatment of
certain types of adult T-cell leukemia and peripheral T-
cell lymphoma. A clinical study of mogamulizumab for
the treatment of CCR4-negative advanced or recurrent
solid cancer is now conducted [28]. CC17 and CCL22
are both ligands of CCR4 but they probably have
opposing effects on Treg homeostasis in that CCL22
favors Treg recruitment whereas CCL17 has been
reported to convert the Treg phenotype to an inflam-
matory mediator [29, 30].
Fig. 2 Overall survival (OS) and Recurrence-free survival (RFS) analyses of patients with ccRCC based on CCL17 expression. Kaplan-Meier analysis
of OS in All Patients group (n = 286) (a); and in SSIGN low-risk group (n = 218) (b); in SSIGN mediate- and high-risk group (n = 68) (c); Kaplan-Meier
analysis of RFS in All Patients group (n = 262) (d); in SSIGN low-risk group (n = 156) (e); in SSIGN mediate- and high-risk group (n = 106) (f). P value
was calculated by log-rank test
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However, some limitations remained to be solved. This
was a retrospective study in nature and the number of
patients enrolled was limited. Though bootstrap internal
validation has been used, the issues of over-fitting still
existed. Cohort-specific biases including the method of
tissue fixation, the staining protocols, the lot of the anti-
body, preparation and storage of the slides could largely
affect our conclusions. Since all patients were from one
institution, patient ethnicity/race, clinical practices at the
institution and selection biases could also lead to
cohort-specific biases thus affected the results. Lack of
external validation was the major limitations of our re-
search. We need to validate the results in an independent
cohort to support our conclusions in the future. Moreover,
Table 2 Proportional hazard model for overall survival and recurrence-free survival prediction
Variables OS (n = 286) RFS (n = 262)
HR (95%CI) P-value† p-value†
(bootstrap‡)
HR (95%CI) P-value† p-value†
(bootstrap‡)
Pathological T stage <0.001 <0.001
pT1 Reference Reference
pT2 2.655 (1.361–5.180) 0.004 0.005 2.586 (1.197–5.587) 0.016 0.011
pT3 2.879 (1.756–4.720) <0.001 0.001 3.061 (1.795–5.221) <0.001 0.002
pT4 3.809 (1.054–14.422) 0.027 0.292 8.842 (2.712–28.823) <0.001 0.009
Distant metastasis
Yes vs No 2.467 (1.283–4.744) 0.007 0.073
Fuhrman grade 0.005 0.001
1 Reference Reference
2 1.957 (0.701–5.466) 0.200 0.219 1.439 (0.563–3.674) 0.447 0.490
3 4.067 (1.353–12.223) 0.012 0.012 4.024 (1.433–11.301) 0.008 0.019
4 6.786 (1.494–30.828) 0.013 0.002 5.377 (1.258–22.981) 0.023 0.005
Necrosis
Present vs Absent 2.180 (1.216–3.909) 0.009 0.063 2.191 (1.202–3.991) 0.010 0.018
ECOG PS
0 vs ≥1 2.123 (1.333–3.382) 0.002 0.004 2.356 (1.426–3.893) 0.001 0.002
CCL17 expression
High vs Low 0.504 (0.309–0.824) 0.006 0.011 0.448 (0.267–0.751) 0.002 0.025
ECOG PS Eastern Cooperative Oncology Group performance status, HR hazard ratio, CI confidence interval, OS overall survival, RFS recurrence-free survival
P-value < 0.05 was regarded as statistically significant
†Data obtained from the Cox proportional hazards model, ‡Bootstrapping with 1000 resamples were used
Table 3 Comparison of the predictive accuracy of the prognostic models
Models Overall survival Recurrence-free survival
C-index (95%CI) Coefficient (95%CI) P-value C-index (95%CI) Coefficient (95%CI) P-value
CCL17 0.615 (0.563–0.667) 0.612 (0.555–0.670)
TNM 0.706 (0.652–0.760) 0.658 (0.601–0.719)
TNM + CCL17 0.751 (0.699–0.803) 0.045 (0.016–0.074) 0.003† 0.717 (0.657–0.776) 0.018 (0.022–0.093) 0.002†
SSIGN 0.632 (0.580–0.685) 0.674 (0.617–0.731)
SSIGN + CCL17 0.679 (0.620–0.738) 0.017 (0.014–0.079) 0.006† 0.720 (0.661–0.778) 0.045 (0.019–0.071) 0.001†
UISS 0.735 (0.688–0.781) 0.710 (0.658–0.762)
UISS + CCL17 0.771 (0.724–0.818) 0.036 (0.017–0.055) <0.001† 0.752 (0.697–0.802) 0.047 (0.018–0.065) 0.001†
Nomogram 0.799 (0.754–0.844) 0.787 (0.735–0.840)
Nomogram vs SSIGN 0.167 (0.118–0.215) <0.001‡ 0.109 (0.064–0.155) <0.001‡
Nomogram vs UISS 0.064 (0.030–0.099) <0.001‡ 0.073 (0.031–0.115) =0.001‡
C-index and 95%CI were calculated from 1000 bootstrap samples to protect from overfitting
C-index concordance index, CI confidence interval, SSIGN Mayo clinic stage, size, grade, and necrosis score, UISS UCLA Integrated Staging System
†Compared the c-index with the original model without CCL17 expression data; ‡ Compared the c-index of nomogram with SSIGN/UISS stratification in different
patient groups
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Fig. 3 (See legend on next page.)
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the heterogeneity of tumors might also affect the results
though we took two tissue cores and took six shots from
one tumor block. Further researches were required to
investigate the roles of CCL17 in ccRCC tumor cells.
Conclusion
In conclusion, we have identified that low CCL17 expres-
sion was strongly associated with a poor outcome and
CCL17 can be used as a novel prognostic factor in pre-
dicting patients’ OS and RFS. We also developed nomo-
grams for OS and RFS, which could give a better
prediction for patients with ccRCC after surgery.
Additional file
Additional file 1: Table S1. Univariate analyses of characteristics
associated with overall survival and recurrence-free survival. (DOC 58 kb)
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